Key facts today
Eli Lilly's weight-loss drug Zepbound is seeing strong sales, with about 30% of weekly prescriptions via its LillyDirect service. Total sales are expected to reach nearly $13 billion in 2025.
Eli Lilly's oral weight-loss drug, orforglipron, is expected to lead the market, competing with Structure Therapeutics' aleniglipron, which has shown promising mid-stage trial results.
Macquarie Capital analysts noted Eli Lilly's Mounjaro may capture market share from rivals like Novo Nordisk in China, impacting GLP-1 drug pricing as it gains reimbursement.
425 ARS
9.70 T ARS
41.24 T ARS
About Eli Lilly and Company
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
ARDEUT111192
FIGI
BBG000HFTQS8
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Related stocks
Eli Lilly (LLY) Shares Have Surged by Around 30% in NovemberEli Lilly (LLY) Shares Have Surged by Around 30% in November
The price action of Eli Lilly and Company (LLY), the world’s largest pharmaceutical firm, reflects exceptionally strong demand:
→ since the start of the month, LLY shares have risen by roughly 30%;
→ in late November, the company’s marke
$LLYThe technical structure for NYSE:SMR presents a compelling case of a strong, sustained uptrend, characterized by a rhythmic pattern of sharp advances followed by periods of consolidation. This behavior is the hallmark of a healthy, momentum-driven bull move.
1. Pattern Analysis: Sequential Bull F
Lilly (NYSE: $LLY) Jumps as FDA Expands Jaypirca UseEli Lilly and Company (NYSE: NYSE:LLY ) received a major regulatory boost after the U.S. Food and Drug Administration approved an expanded indication for its non-covalent BTK inhibitor, Jaypirca (pirtobrutinib). The drug is now approved for adults with relapsed or refractory chronic lymphocytic leu
LLY Hits Major Resistance: Breakout to $1300 or Pullback Ahead?LLY is moving inside a strong long-term ascending channel, and the price has now reached the upper resistance boundary of the purple channel.
This is a major decision zone:
Either a breakout occurs and momentum continues strongly upward,
or the price gets rejected and pulls back inside the channe
Eli Lilly: The Trillion-Dollar Cure for Market Volatility?Eli Lilly has officially shattered the Silicon Valley ceiling, becoming the first healthcare company to achieve a $1 trillion market capitalization. While tech giants like Nvidia grapple with bubble concerns and doubts about AI monetization, Lilly has delivered tangible, recurring revenue through it
Eli Lilly Hits $1 Trillion Milestone on GLP-1 BoomEli Lilly & Co. (NYSE: NYSE:LLY ) briefly crossed the $1 trillion market-cap threshold, becoming the first health-care company in history to reach the valuation. Shares traded around $1,059 as demand for its GLP-1 weight-loss and diabetes drugs exploded, driving extraordinary revenue growth and sol
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
XS238628644
Eli Lilly and Company 1.625% 14-SEP-2043Yield to maturity
5.67%
Maturity date
Sep 14, 2043
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044Yield to maturity
5.65%
Maturity date
Jun 15, 2044
US532457BU1
Eli Lilly and Company 4.15% 15-MAR-2059Yield to maturity
5.57%
Maturity date
Mar 15, 2059
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065Yield to maturity
5.56%
Maturity date
Oct 15, 2065
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065Yield to maturity
5.54%
Maturity date
Feb 12, 2065
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064Yield to maturity
5.53%
Maturity date
Feb 9, 2064
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064Yield to maturity
5.52%
Maturity date
Aug 14, 2064
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063Yield to maturity
5.51%
Maturity date
Feb 27, 2063
LLY6153502
Eli Lilly and Company 5.55% 15-OCT-2055Yield to maturity
5.46%
Maturity date
Oct 15, 2055
US532457BT4
Eli Lilly and Company 3.95% 15-MAR-2049Yield to maturity
5.46%
Maturity date
Mar 15, 2049
LLY5750031
Eli Lilly and Company 5.0% 09-FEB-2054Yield to maturity
5.45%
Maturity date
Feb 9, 2054
See all LLY bonds













